Atherogenic Index of Plasma Predicts the Onset and Progression of Cardio‐Renal‐Metabolic Multimorbidity: Evidence From a Nationwide Prospective Cohort Study

Cardio‐renal‐metabolic (CRM) multimorbidity, defined by the co‐occurrence of cardiovascular disease (CVD), chronic kidney disease (CKD), and type 2 diabetes (T2DM), poses a growing burden for multimorbidity management. The atherogenic index of plasma (AIP), a lipid‐based marker of insulin resistance, may help predict CRM progression, but its prognostic value remains unclear.